Atopic Dermatitis

In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.

The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study.  (©Dzm1try/Shutterstock.com)

Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review.

A summary of treatments for atopic dermatitis in children. 

Physicians spell out knowns and unknowns associated with treating pediatric atopic dermatitis.

Mapping the human genome for chronic itch holds the potential to develop targeted therapy for atopic dermatitis and psoriasis itch, a study shows.

Study shows that blocking IL-13 improves atopic dermatitis ― a promising finding for IL-13 atopic dermatitis drugs in development.

Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.

 FDA approves early, pre-approval trials for pediatric cases

The skin care industry promotes products designed for sensitive skin, yet dermatologists are concerned about the use of skin care products for skin disease.

Observational study shows high heart disease risk in severe and predominantly active atopic eczema.

For some patients with moderate to severe atopic dermatitis, the combination of dupilumab and corticosteroids may be necessary to control flares, a new study shows. Dupilumab is a proven treatment for AD, so where do we go from here? A physician writing in BJD suggests predictive modeling.

Skin biopsies from infants with atopic dermatitis feature important differences compared to adults with atopic dermatitis. These differences could change atopic dermatitis treatment for infants and toddlers with the disease, a study shows.

Three patients achieve 80-100 percent clearance of moderate-to-severe dyshidrosis of the hands and palms after treatment with dupilumab.

Symptomatic relief remains out of reach for many who suffer chronic pruritis. Without drugs specifically approved to treat chronic itch, providers and patients rely on therapies with limited efficacy. Here’s an update of two important clinical trials.

A phase two study of adults with moderate-to-severe atopic dermatitis shows that once-daily oral Janus kinase (JAK) 1 and 2 inhibitor baricitinib relieved itch and improved sleep, a study shows.

The transcription factor "retinoid-related orphan receptor-alpha" (RORA) has been identified as a regulator of T regulatory (Treg) genes responsible for suppressing allergic skin inflammation, researchers report.

The duration of methotrexate administration proves to be longer than that of cyclosporine in atopic dermatitis, according to a small study that compared the two first-line immunosuppressive treatments for atopic dermatitis.

This week during the annual meeting of the American Academy of Dermatology in San Diego, Robert Sidbury, M.D., addressed developments in atopic dermatitis treatments since the publication of treatment guidelines in 2014.

New data and status updates for atopic dermatitis treatments in clinical trials will be presented at the American Academy of Dermatology annual meeting in San Diego this week. In this article, we offer some highlights.

A daily capsule of a cocktail of probiotics may reduce both the severity symptoms in moderate atopic dermatitis and the need for topical corticosteroids to treat symptom flare ups in children.

All children, but healthy controls, had a higher likelihood of behavioral issues. ADHD symptoms of attention, hyperactivity and impulse control, were higher in AD children. Quality of life lower in affected children.

In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.